IBD: Ulcerative Colitis
Biosimilars for IBD: Making the Transition Webinar
On May 28th, Dr. McCurdy answered the following questions in a very informative webinar presentation on Biosimilars:
- What’s the difference between a reference biologic drug and a biosimilar?
- Biosimilars: What’s Health Canada saying?
- What is the clinical evidence to date?
- How do doctors go about transitioning their patients from a reference biologic drug to a biosimilar?
Watch this webinar now!
Related Articles
Making informed decisions is imperative to your good health but understanding the benefits and risks associated with IBD therapy options can be challenging. CDHF developed the […]
#CDHFTalks: Dietary Updates and Recommendations for the IBD patient on a Biosimilar. If you have recently been diagnosed with Inflammatory Bowel Disease (IBD): Crohn’s disease or […]